Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

Wells, John A; Glassman, Adam R; Ayala, Allison R; Jampol, Lee M; Aiello, Lloyd Paul; Antoszyk, Andrew N; Arnold-Bush, Bambi; Baker, Carl W; Bressler, Neil M; Browning, David J; Elman, Michael J; Ferris, Frederick L; Friedman, Scott M; Melia, Michele; Pieramici, Dante J; Sun, Jennifer K; Beck, Roy W

Wells, John A; Glassman, Adam R; Ayala, Allison R; Jampol, Lee M; Aiello, Lloyd Paul; Antoszyk, Andrew N; Arnold-Bush, Bambi; Baker, Carl W; Bressler, Neil M; Browning, David J; Elman, Michael J; Ferris, Frederick L; Friedman, Scott M; Melia, Michele; Pieramici, Dante J; Sun, Jennifer K; Beck, Roy W.

N Engl J Med ; 372(13): 1193-203, 2015 Mar 26.

Article in En | MEDLINE | ID: mdl-25692915

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; Diabetic Retinopathy/drug therapy; Macular Edema/drug therapy; Receptors, Vascular Endothelial Growth Factor/administration & dosage; Recombinant Fusion Proteins/administration & dosage; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Visual Acuity/drug effects; Adult; Aged; Angiogenesis Inhibitors/administration & dosage; Antibodies, Monoclonal, Humanized/adverse effects; Bevacizumab; Double-Blind Method; Female; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Receptors, Vascular Endothelial Growth Factor/adverse effects; Recombinant Fusion Proteins/adverse effects; Retina/drug effects; Retina/pathology; Therapeutic Equivalency

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Recombinant Fusion Proteins / Visual Acuity / Macular Edema / Receptors, Vascular Endothelial Growth Factor / Vascular Endothelial Growth Factor A / Diabetic Retinopathy / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Guideline Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google